Resumo do NICE

As recomendações neste tópico do Best Practice são baseadas em diretrizes internacionais autorizadas, complementadas por evidências e opiniões de especialistas relevantes para a prática recentes. Para seu maior benefício resumimos abaixo as principais recomendações das diretrizes do NICE relevantes.

Principais recomendações do NICE sobre diagnóstico

This summary covers stable chronic obstructive pulmonary disease (COPD; includes emphysema and chronic bronchitis), but not acute exacerbations, in people aged ≥16.

Suspect COPD in people over 35 years who have a risk factor (generally smoking or a history of smoking) and who present with 1 or more of the following symptoms:

  • Exertional breathlessness

  • Chronic cough

  • Regular sputum production

  • Frequent winter 'bronchitis'

  • Wheeze.

When considering a diagnosis of COPD, ask the person if they have:

  • Weight loss

  • Reduced exercise tolerance

  • Waking at night with breathlessness

  • Ankle swelling

  • Fatigue

  • Occupational hazards

  • Chest pain (uncommon)

  • Haemoptysis (uncommon).

    Chest pain and haemoptysis are uncommon in COPD and raise the possibility of alternative diagnoses.

Use the Medical Research Council (MRC) dyspnoea scale to grade breathlessness.

Suspect cor pulmonale in people with:

  • Peripheral oedema

  • A raised venous pressure

  • A systolic parasternal heave

  • A loud pulmonary second heart sound.

    Make the diagnosis of cor pulmonale clinically and exclude other causes of peripheral oedema.

Spirometry and further investigations

Measure post-bronchodilator spirometry to confirm the diagnosis of COPD.

  • Routine spirometric reversibility testing is not necessary as part of the diagnostic process (or to plan initial therapy) for most people.

For people with a post-bronchodilator FEV1/FVC ratio <0.7, assess the severity of airflow obstruction according to the reduction in FEV1:

  • Mild: FEV1 ≥80% predicted

    • For people with mild airflow obstruction, only diagnose COPD if they have 1 or more of the symptoms of COPD (see above)

  • Moderate: FEV1 50% to 79% predicted

  • Severe: FEV1 30% to 49% predicted

  • Very severe: FEV1 <30% predicted (or FEV1 <50% with respiratory failure).

Consider a diagnosis of COPD in younger people who have symptoms of COPD, even when their FEV1/FVC ratio is >0.7.

Consider alternative diagnoses or investigations for older people who have an FEV1/FVC ratio <0.7 but do not have typical symptoms of COPD.

At the time of initial diagnostic evaluation, in addition to spirometry, all patients should have:

  • A chest radiograph to exclude other pathologies

  • A full blood count to identify anaemia or polycythaemia

  • Body mass index (BMI) calculated.

See the NICE guideline for information on when to perform additional investigations (including reversibility testing), when to reconsider the diagnosis, and further guidance on assessing severity and using prognostic factors.

Link para a orientação do NICE

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115) July 2019. https://www.nice.org.uk/guidance/ng115

Principais recomendações do NICE sobre tratamento

Refer to the full NICE guideline and your local drug formulary for further information when prescribing – including dose, contraindications, cautions, safety issues, adverse effects, drug interactions, and monitoring requirements. Please be aware that some of the following indications for medications may not be licensed by the manufacturer (i.e., the use of the medication is 'off-label').

Document an up-to-date smoking history (including pack years) for everyone with COPD.

  • At every opportunity, advise and encourage every person with COPD who is still smoking (regardless of age) to stop, and offer appropriate support and interventions.

Offer pneumococcal vaccination and an annual flu vaccination to all people with COPD.

Develop and regularly review an individualised self-management plan with the person (include COPD education and, if at risk of exacerbations, an exacerbation action plan).

  • See the NICE guideline for more information on education and self-management.

Consider anxiety or depression (particularly in people with severe breathlessness, hypoxia, or attendance at or admission to hospital with an exacerbation) and manage appropriately.

Be aware that inappropriate oxygen therapy in people with COPD may cause respiratory depression.

Multidisciplinary care and referral

COPD care should be delivered by a multidisciplinary team (e.g., respiratory nurse specialists, physiotherapy, dietetics, palliative care, occupational therapy, social services).

Refer for specialist advice when clinically indicated. Reasons for referral include:

  • Diagnostic uncertainty or the person with COPD requests a second opinion

  • Suspected severe COPD

  • Onset of cor pulmonale

  • Assessment for:

    • Oxygen therapy (including measurement of blood gases)

    • Long-term nebuliser therapy (to exclude inappropriate prescriptions)

    • Oral corticosteroid therapy (to justify need for continued treatment or supervise withdrawal)

    • Pulmonary rehabilitation

    • A lung volume reduction procedure or lung transplantation

  • Bullous lung disease (to identify candidates for lung volume reduction)

  • Rapid decline in FEV1 (to encourage early intervention)

  • Dysfunctional breathing (to confirm diagnosis, optimise therapy, access therapists)

  • Onset of symptoms under 40 years or family history of alpha-1 antitrypsin deficiency

    • Offer people with alpha-1 antitrypsin deficiency a referral to a specialist centre

  • Symptoms disproportionate to lung function deficit (to look for other explanations, e.g., cardiac impairment, pulmonary hypertension, depression and hyperventilation)

  • Frequent infections (to exclude bronchiectasis)

  • Haemoptysis (to exclude carcinoma of the bronchus).

See the NICE guideline for more information on when to consider referral for assessments (e.g., for oxygen or nebuliser therapy, pulmonary rehabilitation, lung volume reduction or lung transplantation), and when to involve different members of the multidisciplinary team.

Inhaled therapy: short-acting bronchodilators

Use short-acting bronchodilators (i.e., short-acting beta-2 agonists [SABA], short-acting muscarinic antagonists [SAMA]), as necessary, as the initial empirical treatment to relieve breathlessness and exercise limitation.

Inhaled therapy: combination therapy

Inhaled combination therapy refers to combinations of long-acting muscarinic antagonists (LAMA), long-acting beta-2 agonists (LABA), and inhaled corticosteroids (ICS).

Do not use oral corticosteroid reversibility tests to identify which people should be prescribed ICS, because they do not predict response to ICS therapy.

Do not assess the effectiveness of bronchodilator therapy using lung function alone. Include a variety of other measures such as improvement in symptoms, activities of daily living, exercise capacity, and rapidity of symptom relief.

For people with spirometrically confirmed COPD who remain breathless or have exacerbations despite using a short-acting bronchodilator, having used or been offered treatment for tobacco dependence (if they smoke), and having optimised non-pharmacological management and relevant vaccinations:

  • Offer LAMA+LABA to people who do not have asthmatic features/features suggesting steroid responsiveness (e.g., any previous secure diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time [≥400 ml] or substantial diurnal variation in peak expiratory flow [≥20%])

  • Consider LABA+ICS for people who have asthmatic features/features suggesting steroid responsiveness.

People who are using long-acting bronchodilators outside of the above recommendations (whose symptoms are under control) can continue with their current treatment until both they and their healthcare professional agree it is appropriate to change.

Before starting LAMA+LABA+ICS (triple inhaled therapy), conduct a clinical review to ensure that:

  • Non-pharmacological COPD management is optimised

  • Treatment for tobacco dependence has been used or offered (if the person smokes)

  • The person’s day-to-day symptoms and/or acute episodes of worsening symptoms are caused by COPD, and not by another physical or mental health condition.

For people with COPD who are taking LABA+ICS, offer LAMA+LABA+ICS if:

  • Their day-to-day symptoms continue to adversely impact their quality of lifeor

  • They have a severe exacerbation (requiring hospitalisation)or

  • They have 2 moderate exacerbations within a year.

For people with COPD who are taking LAMA+LABA, consider:

  • LAMA+LABA+ICS if:

    • They have a severe exacerbation (requiring hospitalisation)or

    • They have 2 moderate exacerbations within a year

  • A trial of LAMA+LABA+ICS (lasting for 3 months only) if their day-to-day symptoms adversely impact their quality of life. After 3 months, conduct a clinical review to establish whether the trial has improved their symptoms:

    • If symptoms have not improved, stop LAMA+LABA+ICS and switch back toLAMA+LABA

    • If symptoms have improved, continue with LAMA+LABA+ICS.

Document the reason for continuing ICS use in clinical records and review at least annually.

See the NICE guideline for information on choosing delivery systems for inhaled therapy.

Oral therapy

Long-term use of oral corticosteroid therapy in COPD is not normally recommended.

  • Some people with advanced COPD may need long-term oral corticosteroids when these cannot be withdrawn following an exacerbation. In these cases, the dose of oral corticosteroids should be kept as low as possible.

Theophylline (slow-release formulations) should only be used after a trial of short-acting bronchodilators and long-acting bronchodilators, or for people who are unable to use inhaled therapy, as plasma levels and interactions need to be monitored.

  • Assess the effectiveness of theophylline by improvements in symptoms, activities of daily living, exercise capacity and lung function.

Consider oral mucolytic therapy for people with a chronic cough productive of sputum.

  • Only continue mucolytic therapy if there is symptomatic improvement (e.g., reduction in frequency of cough and sputum production).

  • Do not routinely use mucolytic therapy to prevent exacerbations in stable COPD.

Consider azithromycin prophylaxis for people with COPD who do not smoke if they:

  • Have optimised non-pharmacological management and inhaled therapies, relevant vaccinations and (if appropriate) have been referred for pulmonary rehabilitationand

  • Continue to have 1 or more of the following, particularly if they have significant daily sputum production:

    • Frequent (typically ≥4 per year) exacerbations with sputum production

    • Prolonged exacerbations with sputum production

    • Exacerbations resulting in hospitalisation.

Before starting prophylactic antibiotic therapy in a person with COPD:

  • Consider the need for respiratory specialist inputand

  • See the NICE guideline for full criteria and guidance for the use of prophylactic antibiotics (including necessary investigations prior to use).

Roflumilast is an option that can be started by a specialist for severe COPD in adults with chronic bronchitis and ≥2 exacerbations in the previous 12 months despite triple inhaled therapy.

Anti-tussive therapy should not be used in the management of stable COPD.

Treatment with alpha-tocopherol and beta-carotene supplements, alone or in combination, is not recommended.

Biological therapy for uncontrolled COPD

Mepolizumab and dupilumab are options for add-on maintenance treatment in selected adults with uncontrolled COPD and raised blood eosinophils. See the NICE guideline for more information.

Follow-up

Review people with COPD at least once per year and more frequently if indicated. Follow-up in primary care should cover the following in all people with COPD:

  • Smoking status and motivation to quit

    • Offer advice and treatment to help them stop smoking, and referral to specialist stop smoking services

  • Adequacy of symptom control (including breathlessness, exercise tolerance, and estimated exacerbation frequency)

  • Need for pulmonary rehabilitation

  • Presence of complications

  • Effects of each drug treatment

  • Inhaler technique

  • Need for referral to specialist and therapy services

  • Measurement of FEV1 and FVC

    • Record the values of spirometric tests performed at diagnosis (both absolute and percent predicted)

    • Record the opportunistic measurement of spirometric parameters (a loss of ≥500 ml over 5 years will show which people have rapidly progressing disease and may need specialist referral and investigation)

  • Calculation of BMI and MRC dyspnoea score

    • Pay attention to weight changes (particularly >3 kg) in older people.

People with very severe (stage 4) COPD who are being reviewed in primary care should be seen at least twice per year. Follow-up in primary care should pay specific attention to the following issues in addition to the above:

  • Presence of cor pulmonale

  • Need for long-term oxygen therapy

  • Nutritional state

  • Presence of depression

  • Need for social services and occupational therapy input

  • Measurement of SaO₂.

For most people with stable severe COPD regular hospital review is not necessary.

  • Specialists should regularly review people with severe COPD who need interventions such as long-term non-invasive ventilation.

© NICE (2019) All rights reserved. Subject to Notice of rights NICE guidance is prepared for the National Health Service in England https://www.nice.org.uk/terms-and-conditions#notice-of-rights. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Link para a orientação do NICE

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115) July 2019. https://www.nice.org.uk/guidance/ng115

O uso deste conteúdo está sujeito ao nosso aviso legal